

DAFTAR PUSTAKA

- American Cancer Society. 2020. About Melanoma Skin Cancer. Availabel from: <https://www.cancer.org/cancer/melanoma-skin-cancer/about.html> (Accessed 30 September 2021).
- Behjati, S., Tarpey, P.S., 2013. What is next generation sequencing? *Arch Dis Child Educ Pract Ed.* 98, 236–238.
- Bosserhoff, A.K., 2017. Melanoma Development: Molecular Biology, Genetics and Clinical Application. Springer. 1-433.
- Cai, Y., Ke, L., Zhang, W., Lu, J., Chen, Y. 2021. Recurrent *KRAS* Mutation and Co-mutation of *KIT* and *SF3B1* in Melanoma of the Female Genital Tract. DOI:10.21203/rs.3.rs-200381/v1.
- Calonje E., Lewis F., Bunker C., Martínez DFS., Cubilla A L. 2020. Melanoma. Calonje, E.J, ed. McKee's Pathology of the Skin With Clinical Correlations. Elsevier Limited, 470-558.e20.
- Choi, D.Y., Lee, S.P., Park, S., 2014. Prevalence of *BRAF* and *NRAS* Mutations and a Comparative Analysis in Primary and Metastatic Melanoma of Korean Patients. *Ewha Med J.* 37, 30.
- Cicenas, J., Tamosaitis, L., Kvederaviciute, K., Tarvydas, R., Staniute, G., Kalyan, K., Meskinyte-Kausiliene, E., Stankevicius, V., Valius, M. 2017. *KRAS*, *NRAS* and *BRAF* mutations in colorectal cancer and melanoma. *Med Oncol.* 34(26), 1-11.
- Cichorek, M., Wachulska, M., Stasiewicz, A., Tyimińska, A., 2013. Skin melanocytes: biology and development. *Postepy Dermatol Alergol.* 30, 30–41.
- Colombino, M., Capone, M., Lissia, A., Cossu, A., Rubino, C., De Giorgi, V., *et al.*, 2012. *BRAF*/*NRAS* mutation frequencies among primary tumors and metastases in patients with melanoma. *J. Clin. Oncol.* 30, 2522–2529.
- Cosgarea I, Ugurel S, Sucker A, Livingstone E, Zimmer L, Ziemer M, Utikal J, Mohr P, Pfeiffer C, Pföhler C, Hillen U, Horn S, Schadendorf D, Griewank KG, Roesch A. 2017. Targeted next generation sequencing of mucosal melanomas identifies frequent *NF1* and *RAS* mutations. *Oncotarget.* Jun 20;8(25):40683-40692.

- Corvino, A., Corvino, F., Catalano, O., Sandomenico, F., Petrillo, A., 2017. The Tail and the String Sign: New Sonographic Features of Subcutaneous Melanoma Metastasis. *J. ultrasmedbio.* 370-374.
- Curtin, J.A., Fridlyand, J., Kageshita, T., Patel, H.N., Busam, K.J., Kutzner, H., *et al.*, 2005. Distinct Sets of Genetic Alterations in Melanoma. *N Engl J Med.* 353, 2135–2147.
- Del Carpio Huerta, LP., Castells, MM., Palacios, GA., Sullivan, I., Vidal, AG., and Tarruella, MM. 2017. A novel KRAS mutation in metastatic conjunctival melanoma: a case report and literature review. *Melanoma Res* 00:000–000 Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.
- Dietrich, P., Kupha, S., Spruss, T., C Hellerbrand, C., Bosserhoff, A.K. 2017. Wild-type KRAS is a novel therapeutic target for melanoma contributing to primary and acquired resistance to BRAF inhibition. *Oncogene* (2017), 1–15.
- Dimitriou, F., Krattinger, R., Ramelyte, E., Barysch, M.J., Micaletto, S., Dummer, R., Goldinger, S.M., 2018. The World of Melanoma: Epidemiologic, Genetic, and Anatomic Differences of Melanoma Across the Globe. *Curr. Oncol. Rep.* (2018) 20: 87.
- Elder, D.E., Massi, D., Willemze, R., Scolyer, R., 2018. WHO Classification of Skin Tumors. International Agency for Research on Cancer.
- Evrenos, M.K., Temiz, P., Çam, F.S., Yaman, M., Yoleri, L., Ermertcan, A.T., 2018. Clinicopathological characteristics and mutation profile of BRAF and NRAS mutation in cutaneous melanomas in the Western Turkish population. *Turk J Med Sci.* 48, 973–979.
- El agy F, el Bardai S, El Otmani I, Benbrahim Z, Karim IMH, Mazaz K, *et al.* (2021) Mutation status and prognostic value of KRAS and NRAS mutations in Moroccan colon cancer patients: A first report. *PLoS ONE* 16(3): e0248522. <https://doi.org/10.1371/journal.pone.0248522>.
- Felisiak-Goląbek, A., Inaguma, S., Kowalik, A., Wasąg, B., Wang, Z., Zięba, S., Pięciak, L., Ryś, J., Kopczynski, J., Sarlomo-Rikala, M., Gózdź, S., Lasota, J., Miettinen, M. 2018. SP174 Antibody Lacks Specificity For Nras Q61r And Cross-React With Hras- And Kras-Q61r Mutant Proteins In Malignant Melanoma. *Appl Immunohistochem Mol Morphol.* 2018 January ; 26(1): 40–45.
- Garbe, C., Peris, K., Hauschild, A., Saiag, P., Middleton, M., Bastholt, L., *et al.*, 2016. European Dermatology Forum (EDF), European Association of Dermato-Oncology (EADO), European Organisation for Research and Treatment of Cancer (EORTC), 2016. Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline - Update 2016. *Eur. J. Cancer.* 63, 201–217.

- Gershenwald, J.E., Scolyer, R.A., Hess, K.R., Sondak, V.K., Long, G.V., Ross, M.I., *et al.*, 2017. Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. *CA Cancer J Clin.* 67, 472–492.
- Hamdani C, Ham M.F., Siregar C.S., 2012. Patologi Molekuler. Penerbit Fakultas Kedokteran Universitas Indonesia, Jakarta. 7-114.
- Heppt, M.V., Siepmann, T., Engel, J., Schubert-Fritschle, G., Eckel, R., Mirlach, L., *et al.*, 2017. Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care. *BMC Cancer.* 17, 536.
- He K, Wang Y, Zhong Y, Pan X, Si L, Lu J. 2020. KRAS Codon 12 Mutation is Associated with More Aggressive Invasiveness in Synchronous Metastatic Colorectal Cancer (mCRC): Retrospective Research. *OncoTargets and Therapy.* 2020;13 12601–12613.
- Kaufman, H.L., Mehnert, J.M. (Eds.), 2016. Melanoma, Cancer Treatment and Research. Springer International Publishing. 1-413.
- Kim, S.Y., Yun, S.J., 2016. Cutaneous Melanoma in Asians. *Chonnam Med J.* 52, 185–193.
- Kulski, J., 2016. Next-Generation Sequencing — An Overview of the History, Tools, and "Omic" Applications. pp. 3–60.
- Langer, R., Becker, K., Feith, M., Friess, H., Höfler, H., Keller, G. 2011. Genetic aberrations in primary esophageal melanomas: molecular analysis of c-KIT, *PDGFR*, *KRAS*, *NRAS* and *BRAF* in a series of 10 cases. *Modern Pathology* 24, 495–501.
- Lee, H.Y., Chay, W.Y., Tang, M.B., Chio, M.T., Tan, S.H., 2012. Melanoma: differences between Asian and Caucasian patients. *Ann. Acad. Med. Singap.* 41, 17–20.
- Lilyquist, J., White, K.A.M., Lee, R.J., Philips, G.K., Hughes, C.R., Torres, S.M., 2017. Quantitative Analysis of Immunohistochemistry in Melanoma Tumors. *Medicine Baltimore.* 96.
- Lindberg, M.R., 2017. Diagnostic Pathology: Normal Histology. Elsevier. 42-43.
- Maffeis V, Nicolè L and Cappellesso R. 2019. RAS, Cellular Plasticity, and Tumor Budding in Colorectal Cancer. *Front. Oncol.* 9:1255. doi: 10.3389/fonc.2019.01255.
- Malumbres, M., Pellicer, A., 1998. RAS pathways to cell cycle control and cell transformation. *Front. Biosci.* 3, d887-912.

- Mannan, A and Hahn-Stroemberg, V. 2011. K-ras mutations are correlated to lymph node metastasis and tumor stage, but not to the growth pattern of colon carcinoma. *APMIS* 120: 459–468. DOI 10.1111/j.1600-0463.2011.02852.x.
- Matthews, N.H., LI, W., Qureshi, A.A., Weinstock, M.A., Cho, E., 2017. Epidemiology of Melanoma. Ward W.H., MD and Farma J.M., ed. *Cutaneous Melanoma: Etiology and Therapy*. Australia: Codon publication, 3-22.
- McGrath, J.A., 2020. The structure and function of skin. Calonje, E.J, ed. *McKee's Pathology of the Skin With Clinical Correlations*. Elsevier Limited, 1-34.e3.
- Milagre, C., Dhomen, N., Geyer, F.C., Hayward, R., Lambros, M., Jorge S. Filho, R, and Marais, R. 2010. A Mouse Model of Melanoma Driven by Oncogenic KRAS. *Cancer Res* 2010;70:5549-5557.
- Muñoz-Couselo, E., Adelantado, E.Z., Ortiz, C., García, J.S., Perez-Garcia, J., 2017. NRAS-mutant melanoma: current challenges and future prospect. *Onco Targets Ther.* 10, 3941–3947.
- National Comprehensive Cancer Network (NCCN), 2018, *Melanoma (Version 1.2018)*, Retrieved from <https://www.nccn.org/patients/guidelines/content/PDF/melanoma-patient.pdf>.
- North J. P., Bastian B.C., Lazar A.J. 2020. Melanoma. Calonje, E.J. McKee's Pathology of the Skin With Clinical Correlations. , 5th ed. Elsevier Limited, 1310-1362.e19
- Painter, J.T., Clayton, N.P., Herbert, R.A., 2009. Useful Immunohistochemical Markers of Tumor Differentiation: *Toxicol Pathol.* 389(1), 131-141.
- Patterson, J.W., 2021. Weedon's Skin Pathology. 4th ed. Elsevier Limited.
- Piton, N., Borrini, F., Bolognese, A., Lamy, A and Sabourin, J.C., 2015. KRAS and BRAF Mutation Detection: Is Immunohistochemistry a Possible Alternative to Molecular Biology in Colorectal Cancer?. *Gastroenterol. Res. Pract.* Volume 2015, Article ID 753903, 8 pages <http://dx.doi.org/10.1155/2015/753903>.
- Posch, C., Sanlorenzo, M., Vujic, I., Oses-Prieto, J.A., Cholewa, B.D., Kim, S.T., *et al.*, 2016. Phosphoproteomic Analyses of NRAS(G12) and NRAS(Q61) Mutant Melanocytes Reveal Increased CK2 α Kinase Levels in NRAS(Q61) Mutant Cells. *JID.* 136, 2041–2048.
- Rasmy, A., Fayed, A., Omar, A. Fahmy. 2019. Effect of KRAS mutational status on disease behavior and treatment outcome in patients with metastatic colorectal cancer: intratumor heterogeneity and mutational status. *J Gastrointest Oncol* 2019;10(5):886-895 <http://dx.doi.org/10.21037/jgo.2019.05.04>.

- Rinonce, H.T., Aji, R.P.M., Hayati, N., Pudjohartono, M.F., Kameswari, B., Irianiwati, 2019. Low BRAF V600 mutation prevalence in primary skin nodular melanoma in Indonesia: a real-time PCR detection among Javanese patients. *BMC*. 13, 15.
- Rinonce H.T, Sastri D.J, Trisnawati F, Kameswari B, Ferronika P, Irianiwati. 2022. The frequency and clinicopathological significance of NRAS mutations in primary cutaneous nodular melanoma in Indonesia. *Cancer Rep (Hoboken)*. 5(1):e1454. doi:10.1002/cnr2.1454.
- Saberko,S., Agus,S., Yenny,S.W. 2019. Hubungan Ekspresi Ki-67 dan E-Cadherin dengan kedalaman invasi melanoma malignum berdasarkan clark level. *Majalah Patologi Indonesia* 28 (3), 22-28.
- Saldanha, G., Potter, L., Daforno, P., Pringle, J.H., 2006. Cutaneous melanoma subtypes show different BRAF and NRAS mutation frequencies. *Clin. Cancer Res.* 12, 4499–4505.
- Sheen, Y.-S., Liao, Y.-H., Liao, J.-Y., Lin, M.-H., Hsieh, Y.-C., Jee, S.-H., *et al.*, 2016. Prevalence of BRAF and NRAS mutations in cutaneous melanoma patients in Taiwan. *JFMA*. 115, 121–127.
- Sheen Y.S, Tan K.T, Tse K.P, Liao Y.H, Lin M.H, Chen J.S, Liao J.Y, Tseng Y.J, Lee CH, Hong CH, Liao JB, Chang HT, Chu CY., 2020. Genetic alterations in primary melanoma in Taiwan. *Br J Dermatol*;182(5):1205-1213. doi: 10.1111/bjd.18425. Epub 2019 Oct 15. PMID: 31408190.
- Sontakke,A. S., 2020. Textbook of Human Histology with Color Atlas, 3D Illustrations and Flowcharts. 1st ed CBS Publishers & Distributors Pvt. Ltd.
- Park H.S, Chun Y.J, Kim H.S, Kim J.H, Lee C.K, Beom S.H, Shin S.J, Ahn J.B. 2020. Clinical features and KRAS mutation in colorectal cancer with bone metastasis. *Sci. Rep.*10:21180.
- The Global Cancer Observatory., 2020. GLOBOCAN fact sheets: melanoma skin.
- Thiagalingam, S., 2015. Systems Biology of Cancer. Cambridge University Press. 94-499.
- Timar, J & Kashofer K. 2020. Molecular epidemiology and diagnostics of KRAS mutations in human cancer. *Cancer Metastasis Rev.* <https://doi.org/10.1007/s10555-020-09915-5>.
- Uguen, A., Talagas, M., Costa, S., Samaison, L., Paule, L., Alavi, Z., *et al.*, 2015. NRASQ61R, BRAFV600E immunohistochemistry: a concomitant tool for mutation screening in melanomas. *Diagn Pathol*. 1-10.

- Uhara, H., Ashida, A., Koga, H., Ogawa, E., Uchiyama, A., Uchiyama, R., *et al.*, 2014. NRAS mutations in primary and metastatic melanomas of Japanese patients. *Int J Clin Oncol.* 19, 544–548.
- Usman, H.A., Hernowo, B.S., Tobing, M.D.L., Hindritiani, R., 2018. The Major Role of NF- κ B in the Depth of Invasion on Acral Melanoma by Decreasing CD8+ T Cells. *J Pathol Transl Med.* 52, 164–170.
- Vanni I, Tanda E.T, Dalmasso B, Pastorino L, Andreotti V, Bruno W, Boutros A, Spagnolo F and Ghiorzo P. 2020. Non-BRAF Mutant Melanoma: Molecular Features and Therapeutical Implications. *Front. Mol. Biosci.* 7:172. doi: 10.3389/fmolb.2020.00172.
- Nakamura Y, Yokoyama S, Matsuda K, Tamura K, Mitani Y, Iwamoto H, Mizumoto Y, Murakami D, Kitahata Y, Yamaue H. 2021. Preoperative detection of KRAS mutated circulating tumor DNA is an independent risk factor for recurrence in colorectal cancer. *Sci. Rep.* | (2021) 11:441 |<https://doi.org/10.1038/s41598-020-79909-4>.
- Zhou, Q.-M., Li, W., Zhang, X., Chen, Y.-B., Chen, X.-C., Guan, Y.-X., *et al.*, 2012. The Mutation Profiles of Common Oncogenes Involved in Melanoma in Southern China. *JID.* 132, 1935–1937.
- Zhu X, Meng X, Xiang W, Dai W, Bai Q, Sheng W, Lu Y, Qi P, Wu L, Cai G, Zhou X. 2018. Correlation between clinicopathological features and KRAS, NRAS, and BRAF mutation status in Chinese colorectal cancer patients *Int J Clin Exp Pathol* 2018;11(5):2839-2845.